# Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

> **NCT03282123** · PHASE2 · COMPLETED · sponsor: **Resilient Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** Midomafetamine
- **BEHAVIORAL:** Manualized therapy

## Key facts

- **NCT ID:** NCT03282123
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-16
- **Primary completion:** 2019-08-10
- **Final completion:** 2019-08-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03282123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03282123, "Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03282123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*